Breckenridge Pharmaceutical, Inc., the U.S. subsidiary of Towa International, announced that the Food and Drug Administration has granted approval for its Dehydrated Alcohol Injection, USP, a generic version of Ablysinol developed in partnership with Andersen Pharma Global. The approval represents a significant milestone for patients with hypertrophic obstructive cardiomyopathy who require specialized cardiac intervention.
Product Specifications and Clinical Application
The approved product is a sterile, preservative-free solution containing ≥99% by volume ethyl alcohol with no excipients, packaged in 5 mL single-dose vials. The formulation meets quality and purity standards established by the United States Pharmacopeia. The injection is specifically indicated for inducing controlled cardiac septal infarction to improve exercise capacity in adult patients with symptomatic hypertrophic obstructive cardiomyopathy who are not suitable candidates for surgical myectomy.
Dehydrated Alcohol Injection, USP, will be distributed primarily through hospitals, clinics, and home health care facilities, targeting the institutional healthcare channel where specialized cardiac procedures are performed.
Market Impact and Strategic Positioning
"The approval and launch of our Dehydrated Alcohol Injection, USP, is a significant achievement, positioning Breckenridge as one of the first companies in the U.S. market to offer a generic alternative to Ablysinol," stated Brian Guy, President and Chief Commercial Officer of Breckenridge Pharmaceutical. "This milestone reflects our continued dedication to providing affordable treatment options that meet real patient needs and reinforces our commitment to serving the institutional channel."
The launch aligns with Breckenridge's strategic objectives to expand its presence in the institutional healthcare channel and strengthen its diversified portfolio. The company is introducing a wide range of oncology, autoimmune, rare disease, and supportive care products to the U.S. market as part of its commitment to enhancing patient access to medicines.
Development Partnership and Company Background
The product was developed through a partnership with Andersen Pharma Global, a U.S.-focused company specializing in pharmaceutical product identification, development, manufacturing, and supply. Andersen Pharma has established a track record in delivering affordable medicines and ensuring consistent supply chains for essential therapies.
Breckenridge Pharmaceutical operates as the U.S. subsidiary of Towa International, based in Barcelona, Spain. The approval supports Towa International's global mission of contributing to public health by increasing access to high-quality, affordable therapeutic solutions worldwide. The company partners with manufacturers nationwide and internationally to bring cost-effective generic pharmaceuticals to U.S. patients, emphasizing customer service, on-time delivery, reliable supply, and quality manufacturing standards.
